Drug intelligence / Profile preview

LAS41004 IMP5

Development stage: Phase 2
Lead developer: Almirall
Modality: Small Molecules
Administration: Topical

Overview

LAS41004 IMP5 is a specific topical formulation of the drug LAS41004, developed by Almirall, S.A. It is a combination drug intended for the treatment of mild to moderate plaque psoriasis. The active ingredients are bexarotene, a retinoid, and betamethasone dipropionate, a corticosteroid. Bexarotene functions as a retinoid X receptor agonist, modulating gene expression involved in cell differentiation and proliferation. Betamethasone dipropionate acts as a glucocorticoid receptor agonist, exerting potent anti-inflammatory and immunosuppressive effects. This combination aims to leverage both retinoid and corticosteroid mechanisms to address the complex pathology of psoriasis.

Other names: LAS-41004LAS41004LAS 41004

Targets

GR (Glucocorticoid receptor)RXRA (Retinoid X receptor alpha)

Beyond the preview

Go deeper on LAS41004 IMP5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAS41004 IMP5.

Explore the full profile